PRKCB and glioblastoma: Clinical studies have evaluated the acceptable tolerability of enzastaurin (an inhibitor of PKCβ and PI3K/AKT) in patients with recurrent GBM, but the authors reported that it did not have a superior efficacy of the alkylating agent Lomustine [43, 44].